- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic severe atopic dermatitis;Uncontrolled severe asthma.
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 421KB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 65KB)
Dupilumab – November 2022
Dupilumab: Injection 300 mg in 2 mL single dose autoinjector, Injection 200 mg in 1.14 mL single dose autoinjector; Dupixent®
Last updated
3 March 2023